- Home
- LSPD vs QURE Comparison
LSPD vs QURE Comparison
Compare LSPD & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSPD | QURE |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | LSPD | QURE |
|---|---|---|
| Price | $11.91 | $19.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $13.63 | ★ $58.55 |
| AVG Volume (30 Days) | 457.3K | ★ 2.4M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,157,458,000.00 | $15,751,000.00 |
| Revenue This Year | $15.25 | N/A |
| Revenue Next Year | $11.85 | $158.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.24 | N/A |
| 52 Week Low | $7.34 | $7.76 |
| 52 Week High | $16.74 | $71.50 |
Technical Indicators
Market Signals| Indicator | LSPD | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 27.09 |
| Support Level | $11.12 | $20.55 |
| Resistance Level | $12.69 | $28.50 |
| Average True Range (ATR) | 0.39 | 1.33 |
| MACD | 0.11 | 0.20 |
| Stochastic Oscillator | 53.19 | 7.82 |
Price Performance
Historical ComparisonAbout LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.